Simon Harford
Director of Finance/CFO chez AMICUS THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Simon John Harford currently works at C4X Discovery Holdings Plc, as Non-Executive Director from 2021 and Amicus Therapeutics, Inc., as Chief Financial Officer from 2023.
Mr. Harford also formerly worked at GlaxoSmithKline Pharmaceuticals Ltd., as Non-Executive Director, Avon Products, Inc., as Group Vice President & Controller, Eli Lilly & Co., as Vice President & Controller, PAREXEL International Corp., as Chief Financial Officer & Senior Vice President from 2017 to 2018, GSK Plc, as Senior VP-Finance & Global Pharmaceuticals from 2015 to 2017, and Albireo Pharma, Inc., as Chief Financial Officer & Treasurer from 2018 to 2023.
Mr. Harford received his Masters Business Admin degree from the University of Virginia Darden School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/01/2024 | 164 365 ( 0,06% ) | 2 M $ | 31/03/2024 |
Postes actifs de Simon Harford
| Sociétés | Poste | Début |
|---|---|---|
| C4X DISCOVERY HOLDINGS PLC | Director/Board Member | 20/04/2021 |
| AMICUS THERAPEUTICS, INC. | Director of Finance/CFO | 21/08/2023 |
Anciens postes connus de Simon Harford
| Sociétés | Poste | Fin |
|---|---|---|
| PAREXEL INTERNATIONAL CORPORATION | Director of Finance/CFO | 20/08/2018 |
| GSK PLC | Corporate Officer/Principal | 01/04/2017 |
| ALBIREO PHARMA, INC. | Director of Finance/CFO | - |
| GLAXOSMITHKLINE PHARMACEUTICALS LIMITED | Director/Board Member | - |
| AVON PRODUCTS, INC. | Comptroller/Controller/Auditor | - |
Formation de Simon Harford
| University of Virginia Darden School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| GSK PLC | Health Technology |
| GLAXOSMITHKLINE PHARMACEUTICALS LIMITED | Health Technology |
| C4X DISCOVERY HOLDINGS PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Avon Products, Inc.
 Avon Products, Inc. Household/Personal CareConsumer Non-Durables Avon Products, Inc. engages in the manufacture and marketing of cosmetics and beauty related products. It operates through the following geographical segments: Europe, Middle East and Africa; South Latin America, North Latin America, and Asia Pacific. It offers beauty products such as skincare, fragrance, and color cosmetics; fashion and home items, which consists of fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children's products, and nutritional products. The company was founded by David H. McConnell in 1886 and is headquartered in Northampton, the United Kingdom. | Consumer Non-Durables |
PAREXEL International Corp.
 PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
